Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H Domain

Current Medicinal Chemistry

Volumn 18, Issue 22, 2011, Pages 3335-3342

  Santo, R Di ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diketo acids; Dual inhibitors; HIV 1; IN inhibitor; Integrase; Pyrrole derivatives; Quinolinone drivatives; Reverse transcriptase; Ribonuclease H; RNase H; RNase H inhibitor

Indexed keywords

DIKETO ACID DERIVATIVE; DNA DIRECTED DNA POLYMERASE; DOUBLE STRANDED DNA; ELVITEGRAVIR; INTEGRASE INHIBITOR; OXOACID; RALTEGRAVIR; RIBONUCLEASE H; RIBONUCLEASE H INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CATALYSIS; CHROMOSOME; CONFERENCE PAPER; CYTOTOXICITY; DNA REPLICATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; IC 50; NONHUMAN; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; RNA REPLICATION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME;

HIV INTEGRASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HUMANS; KETO ACIDS; PYRROLES; QUINOLONES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79961078738     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796504619     Document Type: Conference Paper

References (63)

1. Goldgur, Y.; Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Craigie, R.; Davies, D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 9150-9154. (Pubitemid 28506200)
2. Maignan, S.; Guilloteau, J.P.; Zhou-Liu, Q.; Clément-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol., 1998, 282, 359-368. (Pubitemid 28418789)
3. Bujacz, G.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Andrake, M.; Katz, R.A.; Skalka, A.M. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem., 1997, 272, 18161-18168. (Pubitemid 27306402)
4. Yang, W.; Steitz, T.A. Recombining the structures of HIV integrase, RuvC and RNase H. Structure, 1995, 3, 131-134.
5. Beese, L.S.; Steitz, T.A. Structural basis for the 3'-5'exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J., 1991, 10, 25-33. (Pubitemid 21905263)
6. Grobler, J.A.; Stillmock, K.; Hu B.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.S.; Young, S.; Vacca. J.; Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA, 2002, 99, 6661-6666. (Pubitemid 34526189)
7. Marchand, C.; Johnson, A.A.; Karki, R.G.; Pais, G.C.; Zhang, X.; Cowansage, K.; Patel, T.A.; Nicklaus, M.C.; Burke, T.R., Jr.; Pommier, Y. Metaldependent inhibition of HIV-1 integrase byß-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol., 2003, 64, 600-609. (Pubitemid 37048563)
8. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery, 2005, 4, 236-248. (Pubitemid 40372557)
9. Johnson, A.A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr. Top. Med. Chem., 2004, 4, 1059-1077. (Pubitemid 38854857)
10. Dayam, R.; Deng, J.; Neamati, N. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev., 2006, 26, 271-309.
11. Makhija, M.T. Designing HIV integrase inhibitors: Shooting the last arrow. Curr. Med. Chem., 2006, 13, 2429-2441. (Pubitemid 44184645)
12. Lataillade, M.; Kozal, M.J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS, 2006, 20, 489-501. (Pubitemid 44078768)
13. Maurin, C.; Bailly, F.; Cotelle, P. Structure-activity relationships of HIV-1 integrase inhibitors: enzyme-ligand interactions. Curr. Med. Chem., 2003, 10, 1795-1810. (Pubitemid 37038601)
14. Cotelle, P. Patented HIV-1 integrase inhibitors (1998-2005). Recent Patents Anti-Infect. Drug Discovery, 2006, 1, 1-15.
15. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr. Pharm. Des., 2003, 9, 1789-1802.
16. Neamati, N. Patented small molecules inhibitors of HIV-1 integrase: a 10- year saga. Expert Opin. Ther. Patents, 2002, 12, 709-724. (Pubitemid 34537680)
17. Witvrouw, M.; Van Maele, B.; Vercammen, J.; Hantson, A.; Engelborghs, Y.; De Clercq, E.; Pannecouque, C.; Debyser, Z. Novel inhibitors of HIV-1 integration. Curr. Drug. Metab., 2004, 5, 291-304. (Pubitemid 38997443)
18. Young, S.D. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr. Opin. Drug Discov. Devel., 2001, 4, 402-410. (Pubitemid 32678529)
19. Dejesus, E.; Berger, D.; Markowitz, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion, R.; Farthing, C.; Zhong, C.L.; Cheng, A.K.; McColl, D.; Kearney, B.P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatmentexperienced patients. J. Acquired Immune Defic. Syndr., 2006, 43, 1-5. (Pubitemid 44306480)
20. Grinsztejn, B.; Nguyen, B.Y.; Katlama, C.; Gatell, J.M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C.J.; Chen, J.; Harvey, C.M.; Isaacs, R.D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: A phase II randomized controlled trial. Lancet, 2007, 369, 1261-1269. (Pubitemid 46553846)
21. Markowitz, M.; Morales-Ramires, J.O.; Nguyen, B.Y.; Kovacs, C.M.; Steigbigel, R.T.; Cooper, D.A.; Liporace, R.; Schwartz, R.; Isaacs, R.; Gilde, L.R.; Wenning, L.; Zhao, J.; Teppler, H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquired Immune Defic. Syndr., 2006, 43, 509-515. (Pubitemid 44885615)
22. Bacchi, A.; Biemmi, M.; Carcelli, M.; Carta, F.; Compari, C.; Fisicaro, E.; Rogolino, D.; Sechi, M.; Sippel, M.; Sotriffer, C.A.; Sanchez, T.W.; Neamati, N. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by β-diketo acid metal complexes. J. Med. Chem., 2008, 51, 7253-7264.
23. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Deruda, M.; Al-Mawsawi, L.Q.; Neamati, N. From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. J. Med. Chem., 2006, 49, 4248-4260. (Pubitemid 44036668)
24. Telesnitsky, A.; Goff, S.P. in Retroviruses, Coffin, J.M.; Hughes, H; Varmus, H.E. Eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1997, pp. 121-160.
25. Hughes, S.H.; Arnold, E.; Hostomsky, Z. In Ribonucleases H, Crouch, R.J; Toulmé, J.J. Eds. Les Editions Inserm: Paris, 1998; pp.195-224.
26. Nikolenko, G.N.; Palmer, S.; Maldarelli, M.; Mellors, J.W.; Coffin, J.M.; Pathak, V.K. Mechanism for nucleoside analog-mediated abrogation of HIV- 1 replication: Balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA, 2005, 102, 2093-2098. (Pubitemid 40262017)
27. Haren, L.; Ton-Hoang, B.; Chandler, M. Integrating DNA: Transposases and retroviral integrases. Annu. Rev. Microbiol., 1999, 53, 245-281. (Pubitemid 29503732)
28. Klumpp, K.; Hang, J.Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong Kai, P.; Overton, H.; Parkes, K.E.; Cammack, N.; Martin, J.A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res., 2003, 31, 6852-6859. (Pubitemid 37508792)
29. Klumpp, K.; Mirzadegan, T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Drug, 2006, 12, 1909-1922.
30. Keck, J.L.; Goedken, E.R.; Marqusee, S. Activation/attenuation model for RNase H. A one-metal mechanism with second-metal inhibition. J. Biol. Chem., 1998, 273, 34128-34133.
31. Katayanagi, K.; Okumura, M.; Morikawa, K. Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 A resolution: proof for a single Mg(2+)-binding site. Proteins, 1993, 17, 337-347.
32. Mizrahi, V.; Usdin, M.; Harington, A.; Dudding, L. Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase. Nucleic Acids Res., 1990, 18, 5359-5363.
33. Mizrahi, V.; Brooksbank, R.; Nkabinde, N. Mutagenesis of the conserved aspartic acid 443, glutamic acid 478, asparagine 494, and aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase. Expression and biochemical analysis. J. Biol. Chem., 1994, 269, 19245-19249.
34. Andréola, M.L. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "Killing two birds with one stone". Curr. Pharm. Des., 2004, 10, 3713-3723.
35. Yang, W.; Hendrickson, W.A.; Crouch, R.J.; Satow, Y. Structure of ribonuclease H phased at 2 A resolution by MAD analysis of the selenomethionyl protein. Science, 1990, 249, 1398-1405.
36. Davies, J.F., II; Hostomska, Z.; Hostomsky, Z.; Jordan, S.R.; Matthews, D.A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science, 1991, 252, 88-95. (Pubitemid 21916941)
37. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res., 2008, 134, 171-185.
38. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
39. Tramontano, E.; Di Santo, R. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr. Med. Chem., 2010, 17, 2837-2853.
40. Shaw-Reid, C.A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D.B.; Carroll, S.S.; Embrey, M.; Wai, J.S.; Miller, M.D.; Cole, J.L.; Hazuda, D.J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem., 2003, 278, 2777-2780. (Pubitemid 36801178)
41. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res., 2005, 65, 117-124. (Pubitemid 40222288)
42. de Soultrait, V.; Lozach, P.; Altmeyer, R.; Tarrago-Litvak, L.; Litvak, S.; Andréola, M.L. DNA aptamers derivated from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol., 2002, 324, 195-203. (Pubitemid 35379020)
43. Didierjean, J.; Isel, C.; Querré, F.; Mouscadet, J.F.; Aubertin, A.M.; Valnot, J.Y.; Piettre, S.R.; Marquet, R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother., 2005, 49, 4884-4894. (Pubitemid 41778898)
44. Budihas, S.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M.; Parniak, M.; Crouch, R.; McMahon, J.; Beutler, J.; Le Grice, S. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res., 2005, 33, 1249-1256. (Pubitemid 41439918)
45. Semenova, E.A.; Johnson, A.A.; Marchand, C.; Davis, D.A.; Yarchoan, R.; Pommier, Y. Preferential inhibition of the magnesiumdependent strand transfer reaction of HIV-1 integrase byα-hydroxytropolones. Mol. Pharmacol., 2006, 69, 1454-1460.
46. Marchand, C.; Beutler, J.A.; Wamiru, A.; Budihas, S.; Mollmann, U.; Heinisch, L.; Mellors, J.W.; Le Grice, S.F.; Pommier, Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother., 2008, 52, 361-364.
47. Tramontano, E. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target Mini-Rev. Med. Chem., 2006, 6, 727-737. (Pubitemid 43881124)
48. Artico, M.; Di Santo, R.; Costi, R.; Novellino, E.; Greco, G.; Massa, S.; Tramontano, E.; Marongiu, M.E.; De Montis, A.; La Colla, P. Geometrically and conformationally restrained cinnamoyl-compounds as inhibitors of HIV- 1 integrase: synthesis, biological evaluation and molecular modeling. J. Med. Chem., 1998, 41, 3948-3960. (Pubitemid 28483472)
49. Costi, R.; Di Santo R.; Artico, M.; Massa, S.; Ragno, R.; Loddo, R.; La Colla, M.; Tramomtano, E.; La Colla, P.; Pani, A. 2,6-Bis(3,4,5- trihydroxybenzylidene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem., 2004, 12, 199-215. (Pubitemid 38096232)
50. Pluymers, W.; Neamati, N.; Pannecouque, C.; Fikkert, V.; Marchand, C.; Burke, T.R., Jr.; Pommier, Y.; Schols, D.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol., 2000, 58, 641-648.
51. Hazuda, D.J.; Felock, P.; Witmer, M.V.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski L.; Schleif, W.A.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287, 646-650. (Pubitemid 30070911)
52. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; Dornadula, G.; Danovich, R.M.; Witmer, M.V.; Wilson, K.A.; Tussey, L.; Schleif, W.A.; Gabryelski, L.S.; Jin, L.; Miller, M.D.; Casimiro, D.R.; Emini, E.A.; Shiver, J.W. Integrase inhibitors and cellular immunity suppress retroviral replication in rehesus macaques. Science, 2004, 305, 528-532. (Pubitemid 38971345)
53. Di Santo, R.; Costi, R.; Artico, M.; Tramontano, E.; La Colla, P.; Pani, A. HIV-1 integrase inhibitors that block HIV-1 replication in infected cells. Planning synthetic derivatives from natural products. Pure Appl. Chem., 2003, 75, 195-206.
54. Di Santo, R.; Costi, R.; Artico, M.; Ragno, R.; Greco, G.; Novellino, E.; Marchand, C.; Pommier, Y. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Il Farmaco, 2005, 60, 409-417. (Pubitemid 40731526)
55. Costi, R.; Di Santo R.; Artico, M.; Roux, A.; Ragno, R.; Massa, S.; Tramontano, E.; La Colla, M.; Loddo, R.; Marongiu, M.E.; Pani, A.; La Colla, P. 6- Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. Lett., 2004, 14, 1745-1749. (Pubitemid 38340679)
56. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M; Amici, R.; Galluzzo, C.M., Nencioni, L.; Palamara, A.T.; Pommier, Y.; Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities and mechanism of action. J. Med. Chem., 2006, 49, 1939-1945.
57. Di Santo, R.; Costi R.; Roux, A.; Miele, G.; Cuzzucoli Crucitti, G.; Iacovo, A.; Rosi, F.; Lavecchia, A.; Marinelli, L.; Di Giovanni, C.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C.M.; Nencioni, L.; Palamara, A.T.; Pommier, Y.; Marchand, C. Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis and biological activities. J. Med. Chem., 2008, 51, 4744-4750.
58. Bona, R.; Andreotti, M.; Buffa, V.; Leone, P.; Galluzzo, C.M.; Amici, R.; Palmisano, L.; Mancini, M.G.; Michelini, Z.; Di Santo, R.; Costi, R.; Roux, A.; Pommier, Y.; Marchand, C.; Vella, S.; Cara, A. Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds. Antimicrobial Ag. Chemother., 2006, 50, 3407-3417. (Pubitemid 44527517)
59. Cianfriglia, M.; Dupuis, M.L.; Molinari, A.; Verdoliva, A.; Costi, R.; Galluzzo, C.M.; Andreotti, M.; Cara, A.; Di Santo, R.; Palmisano, L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-Pglycoprotein. Retrovirology, 2007, 4, 17.
60. Terrazas-Aranda, K.; Van Herrewege, Y.; Hazuda, D.; Lewi, P.; Costi, R.; Di Santo, R.; Cara, A.; Vanham, G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob. Agents Chemother., 2008, 52, 2544-2554. (Pubitemid 351915687)
61. Jegede, O.; Babu, J.; Di Santo, R.; McColl, D. J.; Weber, J.; Quiñones- Mateu, M.E. HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Rev., 2008, 10, 172-189.
62. Michelini, Z.; Galluzzo, C.M.; Negri, D.R.; Leone, P.R.; Amici, R.; Bona, R.; Summa, V.; Di Santo, R.; Costi, R.; Pommier, Y.; Marchand, C.; Palmisano, L.; Vella, S.; Cara, A. Evaluation of HIV-1 integrase inhibitors on human primari macrophages using a luciferase-based single-cycle phenotypic assay. J. Virol. Methods, 2010, 168, 272-276.
63. Johnson, A.A.; Marchand, C.; Patil, S.S.; Costi, R.; Di Santo, R.; Burke, T.R., Jr.; Pommier, Y. Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays. Mol. Pharmacol., 2007, 71(3), 893-901. (Pubitemid 46294101)